Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies. Under the agreement, Kiora will receive a $1 million upfront payment and is eligible to receive development and...
Read releases like this the second they cross the wire.
1,400+ feeds from 80+ newswires in one live cockpit — saved searches, instant alerts, AI summaries. 72-hour free trial, no card required.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live on PPN World.
PPN Source →